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ABSTRACT
The large use of simple and effective diagnostic tools has significantly con-
tributed to the increase in diagnosis of thyroid cancer over the past years. How-
ever, there is compelling evidence that most micropapillary carcinomas have an
indolent behavior and may never evolve into clinical cancers. Therefore, there is
an urgent need for new tools able to predict which thyroid cancers will remain
silent, and which thyroid cancers will present an aggressive behavior. There are
a number of well-established clinical predictors of malignancy and recent stud-
ies have suggested that some of the patient’s laboratory data and image meth-
ods may be useful. Molecular markers have also been increasingly tested and
some of them appear to be very promising, such as BRAF, a few GST genes and
p53 polymorphisms. In addition, modern tools, such as immunocytochemical
markers, and the measure of the fractal nature of chromatin organization may
increase the specificity of the pathological diagnosis of malignancy and help
ascertain the prognosis. Guidelines designed to select nodules for further evalu-
ation, as well as new methods aimed at distinguishing carcinomas of higher
aggressiveness among the usually indolent thyroid tumors are an utmost neces-
sity. (Arq Bras Endocrinol Metab 2007;51/5:713-722)
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RESUMO
Identificando um Perfil de Risco para Câncer de Tiróide.
O uso cada vez mais freqüente de métodos diagnósticos simples e efetivos tem
contribuído significativamente para um aumento no diagnóstico de câncer da
tiróide nos últimos anos. Entretanto, existem importantes evidências de que
muitos dos microcarcinomas papilíferos têm um comportamento indolente e
podem nunca evoluir para cânceres clínicos. Existe, portanto, uma necessidade
urgente de desenvolver novas ferramentas capazes de predizer quais os tumores
tiroidianos que permanecerão silenciosos e quais desenvolverão comportamen-
to agressivo. Há uma série de marcadores clínicos de evolução bem estabeleci-
dos e alguns estudos recentes sugerem que dados laboratoriais e métodos de
imagem podem ser úteis. Marcadores moleculares também vêm sendo ativa-
mente investigados e alguns, como BRAF, os genes GST e polimorfismos de p53,
parecem promissores. Além disso, marcadores imunocitoquímicos e a medida da
natureza fractal da cromatina podem aumentar a especificidade do diagnóstico
anatomopatológico e ajudar a predizer o prognóstico. Existe uma necessidade
imperiosa de elaborarmos diretrizes destinadas a selecionar os nódulos que
merecem prosseguimento em sua avaliação, assim como novos métodos
capazes de identificar lesões mais agressivas entre os geralmente indolentes
tumores tiroidianos. (Arq Bras Endocrinol Metab 2007;51/5:713-722)
Descritores: Fatores de predisposição; Meio ambiente; Genes de susceptibilidade;
Evolução
RECENT IMPROVEMENTS IN MEDICAL technology have increased the detec-tion of nodular thyroids, raising the incidence of incidental nodules to epi-
demic levels. Indeed, thyroid nodules may be detected in as much as 16% of
imaging studies performed for other purposes on neck and chest computer
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tomography scans, magnetic resonance, carotid Doppler
studies and, especially, ultrasonography (1). The physi-
cian, encountering one of these lesions, is faced with a
dilemma on which is the best course of management of
this incidental finding (2). Fine-needle cytology has been
more frequently indicated in view of the anxiety of most
patients and the lack of reliable parameters of malignan-
cy, this is certainly one of the causes of the increase in
thyroid cancer detection we have been observing over
the past decades (3). Aggressive evaluation of nodular
thyroids has consequently contributed to a sharp increase
in the number of small papillary carcinomas operated (3).
However, there is compelling evidence that most of these
tumors would never evolve clinically.
THYROID CANCER BIOLOGY
Microcarcinomas, defined by the World Health Organi-
zation as carcinomas 1.0 cm or less in diameter, have
been described in 1% to 35.6% of autopsy studies and
5.5% to 10.5% of thyroid glands removed due to causes
other than malignancy (4-11). Considering that thyroid
cancer incidence in Brazil, as in most countries, presents
in no more than 0.3% of men and 1% of women, a great
part of microcarcinomas detected by ultrasonography in
autopsies or surgical specimens will probably never evolve
into clinical cancers (3,12). Searching for indicators of
the clinical evolution of papillary microcarcinomas, we
studied a total of 32 lesions identified during autopsy and
in surgical specimen material. These lesions were found
in 7.8% of the 166 consecutive autopsies examined and
7.2% of 261 thyroids that were surgically removed due to
thyroid diseases in general, with a higher incidence
between the ages of 30 and 49 years (13). Both genders
were similarly affected: 9.3% of men and 8.8% of women
in autopsy series, and 6.2% of men and 7.3% of women
in surgical series, suggesting that hormonal factors may
favor the subsequent development of clinical lesions in
women (14). Indeed, the higher incidence of thyroid
carcinoma in women during reproductive years com-
pared to men, and the increased risk associated with the
therapeutic use of estrogens have suggested a patho-
genetic role exerted by these steroids in the development
of thyroid cancer (14). In addition, gender is a significant
prognostic marker, since women with differentiated thy-
roid carcinomas show a better survival than men in our
own data and that of others (15,16). Recent studies have
provided a new insight into the molecular mechanisms
through which estrogens may induce the progression of
thyroid cancer, demonstrating that the G protein-cou-
pled receptor 30 (GPR30) and the mitogen-activated
protein kinase (MAPK) pathway mediate both the up-
regulation of c-fos and the growth response to 17β-estra-
diol (E2), genistein (G), and 4-hydroxyta-moxifen
(OHT) in thyroid cancer cell cultures (17).
In addition to estrogens, other factors may cer-
tainly take part in the thyroid cancer pathogenetic
process. It is reasonable to think that risk factors of
thyroid cancer may also define tumor behavior and, in
consequence, their outcome. The American Joint
Committee on Cancer and International Union
Against Cancer, together with the National Compre-
hensive Network (AJCC/UICC and NCCN), sum-
marized the risk factors for metastases, recurrence and
fatal outcome, taking into account patient and tumor
data, as demonstrated in table 1 (18).
Unfortunately, most prognostic factors depend
on tumor examination, preventing any other action
before surgical intervention. Prognostic classification
and risk group stratification have improved during the
last two decades with a deeper understanding of the
biology of well-differentiated thyroid tumors. Howev-
er, level 1 evidence is not yet available, there are no
prospective randomized trials based on a variety of
treatments, mainly total versus less than total thy-
roidectomy and surgery versus observation for papil-
lary microcarcinomas. Decisions on thyroid cancer
management are based mainly on retrospective studies
used to define staging systems. The most common
Table 1. Prognostic factors for metastasis, recurrence and death risk from differentiated thyroid carcinomas (18).
Patients Tumor
Age < 15 years or age > 45 years Tumor: large (> 2 cm)
Male gender Localization: multifocal, bilateral
History of familial thyroid cancer Local tumor invasion: beyond the capsule
Subtypes: tall, columnar and Hürthle cell
Nuclear atypia and tumor necrosis: accentuated
Vascular invasion: present
Cervical or mediastinal lymph nodes
Distant metastases
Low or no iodide uptake by the tumor and/or the metastases
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staging system, TNM (tumor, node, metastasis),
which adheres to the biology of tumors, has been
extensively reviewed over the years (19), and has been
successfully used for over 65 years in thyroid cancer
patients (20). However, the literature still lacks an
analysis of the TNM and other scoring systems (OSU,
ACES, AMES, etc.), as well as accuracy and utility
concerning papillary microcarcinomas. Our data indi-
cated that extrathyroidal extension and lymph node
metastases, which are important TNM elements, do
not correlate with outcomes of patients with papillary
microcarcinomas (21). In a cohort of 68 patients with
papillary microcarcinomas followed-up for 103
months (15 to 289 months), we observed no deaths
but a relatively high number (19.1% of the cases) of
unfavorable events, such as local recurrence and even
long-distance metastasis (21). These patients respond-
ed well to the therapeutic measures: 50% of TNM III
or IV PMC patients remained free of disease during
the follow-up. Therefore, TNM alone was not able to
predict favorable or unfavorable outcome of these
patients, as demonstrated in figure 1.
In addition, the independent value for each para-
meter needs to be determined in a multivariate analysis
of all risk factors for each individual patient (22). More-
over, the influence of good number risk factors for dif-
ferentiated thyroid cancer on the prognostics of these
tumors has not been investigated. A population-based
nested case-control study of the 5,554 differentiated
thyroid cancer patients diagnosed in Sweden from 1958
to 1978 investigated the cause of death of thyroid can-
cer patients matched by age at diagnosis, gender, and
period calendar controls (23). The authors aimed to
investigate how factors such as smoking, number of
children, previous thyroid disorders, previous radiother-
apy toward the neck, family history of thyroid diseases
and malignancies influenced survival. The analysis of the
595 cases and controls showed that smokers had a bor-
derline significant increased risk of dying from differen-
tiated thyroid cancer. Previous radiotherapy towards the
neck region had no prognostic implication. A family his-
tory of differentiated thyroid cancer influenced prog-
nostics although not significantly in a few cases (23).
The remaining risk factors studied did not influence sur-
vival. The authors concluded that smokers appeared to
have a worse prognostic compared to nonsmokers, and
a family history of thyroid cancer had a non-significant
negative effect on survival (23). Our data on micropap-
illary carcinomas showed a similar trend (13). Although
associated nodular goiter was observed in 54% of autop-
sies and 26% of surgical specimens, and Hashimoto’s
thyroiditis was observed only in surgical material (15%
of the cases), we were not able to correlate risk of malig-
nancy with any concomitant lesion and we could not
find risk factors for clinical evolution evaluation (13).
However, we observed that the smallest papillary micro-
carcinomas appeared most frequently as nonencapsulat-
ed nonsclerosing tumors without inflammatory infiltrate
or fibrosis, suggesting that they could represent the
early stages of development thereby raising questions
concerning the role of the immune system in delaying
the progression of these tumors (13). There is evidence
that oncogene-induced cytokine secretion is important
for the development and progression of thyroid carci-
nomas in genetically permissive hosts (24). We demon-
strated earlier that the odds for patients with a previous
history of thyroid autoimmune disease (p< 0.02) or
with thyroid autoantibodies (p< 0.001) having a worse
outcome were lower than for patients with no evidence
of autoimmune activity, suggesting that autoimmune
activity against the gland may exert a protective effect
on the outcome of patients with differentiated thyroid
Figure 1. Graphical comparison between TNM classification system and outcomes, defined as favorable or unfavorable, in 68
papillary thyroid microcarcinomas with less than 1 cm in diameter (PMC), and in 358 papillary thyroid carcinomas larger than
1 cm (PTC non-PMC).
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carcinoma (25). Markers of immune activation against
the neoplastic tissue may be useful.
The literature is quite intriguing regarding the
influence of smoking habits on thyroid cancer. Many
epidemiologic observations were not able to associate
cigarette smoking with thyroid cancer and some even
found a lower risk for thyroid cancer among smokers.
Twelve out of 13 case-control studies that examined the
association between cigarette smoking and thyroid can-
cer found the risk of thyroid cancer to be decreased by
40% among smokers (26). Cohort studies, including a
prospective Canadian one, were unable to demonstrate
any association between smoking history and the risk of
thyroid cancer (27). In addition, we were not able to
find any correlation between smoking, clinical features,
parameters of aggressiveness at diagnosis or during fol-
low-up of 248 patients with thyroid nodules, including
67 benign goiters, 13 follicular adenomas, 136 papillary
carcinomas and 32 follicular carcinomas, and 277 con-
trols with similar ethnic backgrounds (28). Why would
smoke influence the outcome of thyroid cancer patients
in the Swedish study (23)? It is possible that other
effects of the many toxic compounds existing in ciga-
rette smoke, on other organs or systems, besides the
thyroid, were responsible for this influence. Neverthe-
less, the role of smoke on thyroid cancer outcome
remains to be elucidated. Likewise, the influence of the
genetic profile and environmental factors on thyroid
cancer biology remains largely unknown.
It has been proposed that incidental cancer
found by histological examination of goiters would hold
lower potential aggressiveness than cancers detected by
fine-needle aspiration considering prognostic features,
such as multifocality, lymph node metastasis and extra-
capsular invasion (29). On the other hand, there are
many reports on the aggressive behavior of papillary
microcarcinomas, which evolve not only with lymphatic
regional metastases, but also with blood-borne lung,
bone and brain metastases (30,31).
What do you know about differentiated thyroid
cancer and how can you use this knowledge in order
to define susceptibility profile and outcome for differ-
entiated thyroid cancer?
ENVIRONMENTAL AND GENETIC RISK FACTORS
FOR DIFFERENTIATED THYROID CARCINOMAS
Thyroid cancer is the most frequent endocrine cancer
with a geographic variation in its incidence and mani-
festations (32). While it does not account for more
than 1% of all human cancers in most countries, in
other regions such as the Middle East, thyroid cancer
is the second most common neoplasm among women
(33). Brazilian data also show a highly distinctive inci-
dence of thyroid tumors in different regions of the
country (12). This great variation in incidence reflects
differences not only in the access to health care and
possibly diverse methods or thoroughness of thyroid
examination, but also in environmental and genetic
characteristics of the populations studied.
Exposure to ionizing radiation, especially dur-
ing childhood, remains the only factor clearly associat-
ed with benign and malignant thyroid tumors in
humans (34), although there is strong epidemiological
evidence pointing towards the involvement of geo-
graphic, ethnic and dietary factors in the risk of spo-
radic thyroid cancer (32,34,35).
The most relevant genetic alterations identi-
fied so far in the different progression stages of thy-
roid tumors include RAS mutations in follicular
tumors (36), RET gene rearrangements and BRAF
mutations in papillary carcinomas (37,38), PPARγ-
PAX8 mutations in follicular carcinomas (39), and
p53 mutations in poorly differentiated and anaplastic
carcinoma (40). There is compelling epidemiologic,
experimental and clinical evidences that exposure to
ionizing radiation may trigger a series of abnormali-
ties related to these genes’ activation or inactivation,
aside from producing genetic instability (41). A low-
level genomic instability may even be a feature of
papillary thyroid carcinoma (42). However, we still
do not understand why some individuals exposed to
ionizing radiation develop thyroid cancer whereas
others do not. The age at exposure has been shown
to be a critical risk factor for developing thyroid car-
cinoma after exposure to fallout from Chernobyl,
with those under the age of 1 showing a much
greater risk than older children. There is a rapid
decline to a level of relatively low risk for young
adults (43,44). A similar situation was portrayed in
Nagasaki and Hiroshima, where atomic bomb sur-
vivors displayed one of the highest solid tumor risk
estimates (45). The likely reasons for this age-related
risk include iodine radioisotope intake, radioiodine
uptake, and biological sensitivity factors. The exis-
tence of biological sensitivity factors is confirmed by
the finding of a similar, although less marked age-
related, sensitivity to thyroid carcinomas after expo-
sure to external radiation (46). Two main reasons for
this sensitivity could be either the mitotic rate at the
time of radiation exposure or the number of mitoses
that occur in the progeny of the mutated cell, or per-
haps both (47).
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What other environmental factors may also con-
tribute to the increasing incidence of cancer, not only
in regions affected by fallout but in other countries as
well?
Iodine has long been recognized as an important
factor in thyroid cancer pathogenesis. Iodine-deficient
thyroid glands will of course show a high radioactive io-
dine uptake, leading to the prediction that risk of deve-
loping thyroid carcinoma after exposure to radiation
would be greater in areas with greater iodine deficiency.
In fact, the type and consequent aggressiveness of thy-
roid tumors seem to be related to the population’s io-
dine intake, although a clear relationship between io-
dine supply to the population and sporadic thyroid can-
cer incidence, as well as its alleged physiopathology are
still unclear (48). This issue is discussed by Nobel and
Medeiros-Neto in another article of this same journal.
Some of the genes related to thyroid carcino-
genesis have been related to tumor aggressiveness and,
hence, to prognostics. Many studies, using both
immunocytochemical and genetic analyses, have
shown that p53 mutations are highly prevalent in
poorly differentiated and undifferentiated thyroid car-
cinomas, as well as in thyroid cancer cell lines (40,49).
However, these mutations are not found in benign
tumors and are infrequent in well-differentiated can-
cers, suggesting that mutational inactivation of p53
occurs at a late stage of thyroid tumor progression and
may represent a key event in the progression from dif-
ferentiated to anaplastic carcinomas (50,51). Prelimi-
nary data of our group using immunohistochemistry
for p53 in 34 papillary carcinomas, including 21 cases
of the classical histological type, 7 tall cell variants and
6 of the follicular variant type; 16 follicular carcino-
mas; 4 medullary and 3 anaplastic carcinomas did not
confirm a relationship between the expression of p53
and prognostics. However, the Kaplan-Meier survival
curve of these patients, displayed in figure 2, suggests
that a longer follow-up and/or a larger cohort may
prove p53 to be a reliable immunohistochemical, and
perhaps even a immunocytochemical, prognostic mar-
ker. Furthermore, we tested the gene MUC, which
was described as overexpressed in aggressive thyroid
carcinomas (52). MUC1 overexpression is a key mol-
ecular event in the pathogenesis of aggressive thyroid
tumors (53). In malignancy, MUC1 looses its polar-
ized expression, redistributes, and is expressed on the
whole cell surface. This redistribution shields other cell
surface molecules from their ligands and interferes
with integrin-mediated adhesion to the extracellular
matrix and with cadherin-mediated cell-cell adhesion.
Increased MUC1 expression thereby promotes cellular
dissociation and oncogenic progression (53). MUC1
upregulation also protects tumor cells from immune
recognition and destruction by the cellular arm of the
immune system. Moreover, it has been shown to
inhibit human T-cell proliferation, thereby contribu-
ting to cancer-propagated immunosuppression (53).
Previous studies from Wreesmann et al. identified
MUC1 expression in thyroid slides (52). We were able
to reproduce this technique, but in the 50 differenti-
ated thyroid tumors studied in a preliminary protocol,
we were not able to associate MUC expression with
the patients’ outcome (figure 3).
Figure 2. Kaplan-Meier survival curve (estimated probability
of survival) of 50 differentiated thyroid cancer patients that
were either immunohistochemically p53 positive or negative
followed-up for 120 months.
Figure 3. Kaplan-Meier survival curve (estimated probabili-
ty of survival) of 50 differentiated thyroid cancer patients that
were either immunohistochemically MUC positive or nega-
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We also investigated a gene that encodes a key
protein for thyroid cancer detection and treatment and
therefore related to patients’ outcome: NIS. The sodi-
um iodide symporter (NIS) protein expression and
functional integrity is essential to assure a radioiodine
uptake high enough to detect and destroy any tumoral
thyroid tissue. The absence of radioiodide uptake is
associated with high recurrence rate and reduced sur-
vival (54). We previously demonstrated that a low
expression of NIS mRNA levels, quantified by real-
time PCR, identifies aggressive thyroid tumors (55).
Unfortunately, we were not able to find any relation-
ship between NIS protein expression and patients’
outcome in the same cohort mentioned above. Once
again, the Kaplan-Meier survival curve of these
patients, displayed in figure 4, suggested that a longer
follow-up and/or a larger cohort may prove NIS to be
a useful immunohistochemical and perhaps even
immunocytochemical prognostic marker, although
our preliminary data were not statistically significant in
terms of outcome prediction.
Other genes directly related to thyroid tumorige-
nesis have actively been investigated as potential pro-
gnostic markers. One of the most exciting is BRAF. In
vitro and in vivo models have demonstrated that over-
expression of activated BRAF induces malignant trans-
formation and aggressive tumor behavior, further dis-
cussed in another article of this issue. BRAF and other
RAF kinases are frequently activated by other thyroid
oncogenes and are important mediators of their biolo-
gical effects, including dedifferentiation and prolifera-
tion. Two large studies showed that BRAF mutation
predicts a poorer clinical prognosis for papillary thyroid
cancer (56,57). However, a recent study from the Pisa
group challenged these studies. A review of 61 papillary
thyroid carcinoma patients with BRAF mutations, fol-
lowed-up for 6 years, did not show evidence of any
prognostic utility for BRAF (58).
In addition to the genes directly related to thy-
roid follicular cell differentiation, low-penetrance
genes or rather polymorphisms in such genes could be
of great significance to understand the tumorigenic
processes of thyroid carcinomas.
DETOXIFICATION SYSTEMS AND THYROID 
CARCINOMA SUSCEPTIBILITY
As discussed, the thyroid cancer etiology is markedly
uncertain. A wide variety of drugs, pesticides, goitrogenic
xenobiotics and chemicals have been shown to increase
the incidence of thyroid tumors in rodents (59-61).
However, chemicals have seldom been associated with
human thyroid cancer, in contrast to lung, bladder, and
many other cancers. No increase in the human thyroid
cancer risk has ever been consistently observed with any
drug (62,63). On the other hand, there is compelling
evidence that environmental factors, besides ionizing
radiation, influence cancer incidence. Thyroid cancer is
the fastest growing type of cancer in the USA with a 6.3%
increase during the period of 1997–2003 and we have
data suggesting that in Brazil it is not different (12,64).
However, the rate of increase as well as the incidence of
thyroid cancer varies in different geographic and ethnic
group regions, including individuals exposed to well-
defined factors, such as ionizing radiation (44-47,64-67).
The question may be posed as to why some individuals
are more susceptible to environmental aggressions? The
biochemical basis for this susceptibility is related to
genetic polymorphisms that normally occur in the gener-
al population regarding genes involved in the predisposi-
tion to a specific cancer, in the metabolic activation or
detoxification of environmental genotoxins, as well as in
controlling DNA repair or cellular damage (67-72).
Several polymorphic genes, encoding for enzymes
involved in the biotransformation of carcinogens, have
been studied as possible cancer risk modifiers. One of the
most primitive defense mechanisms against environmen-
tal carcinogens is a supergene family of dimeric enzymes
that are expressed in probably all life forms, the glu-
tathione S-transferase (73). These enzymes catalyze the
conjugation of glutathione to a variety of electrophiles,
including arene oxides, inorganic arsenic, unsaturated
carbonyls, organic halides and other substrates or oxida-
Figure 4. Kaplan-Meier survival curve (estimated probability
of survival) of 50 differentiated thyroid cancer patients that
were either immunohistochemically NIS positive or negative
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tive stress products (74). We demonstrated that the
inheritance of null forms of genes codifying some of
these enzymes (75), as well as of polymorphic gene vari-
ants that produce less active forms of enzymes (76),
increase the susceptibility to thyroid differentiated can-
cer. Other polymorphic gene systems of defense may be
involved in thyroid cancer risk. Preliminary data from
our group showed that N-acetyl transferase 2 genes as
well are involved in thyroid cancer risk (77).
Among the genes involved in cellular repair,
p53 polymorphism is one of the most interesting. This
polymorphism has been shown to have varying ethnic
and geographical distribution, like most genetic
human polymorphisms. It has been reported to be a
potential genetic risk factor for many types of cancer,
and we as well as others have demonstrated that it is
also involved in thyroid cancer risk (78,79).
Many other systems may possibly be involved in
the complex interaction between human beings and
environment that ultimately leads to cancer. A series of
promising reports identifying polymorphisms in
germline DNA have been published in an effort to delin-
eate polygenic models of thyroid cancer susceptibility
and prognosis (80-82). Such models are particularly
interesting since they may help select individuals for spe-
cific chemopreventive interventions and determine
which patients with nodules or with microcarcinomas are
most likely to benefit from specific therapies. Unfortu-
nately, these studies have produced inconsistent results
mostly derived from small samples but also from popula-
tion stratification secondary to ethnic diversity, hetero-
geneity of the therapeutic measures employed as well as
consideration being limited to only one rather than com-
binations of polymorphisms. In addition, an important
limitation in case-control studies is the fact that some
population controls may have undetected thyroid lesions
that could mislead the interpretation of the observed
associations. Our studies have the advantage of using the
Brazilian population, which presents a highly heteroge-
neous ethnic composition. Nonetheless, larger cohorts
and metanalysis are needed. Hopefully, a panel of mole-
cular markers will be able to identify early on life those at
risk for thyroid cancer, hence helping define preventive
strategies for these individuals in a near future.
PREDICTORS OF THYROID OUTCOME
The thyroid cancer patient needs to be reevaluated at
each clinical appointment. As stated in the Guidelines
also published in this issue of the ABEM, this evalua-
tion outlines the patient’s outcome and defines further
strategies.
Laboratory data
Thyroid hormone suppression lessens disease progres-
sion in high-risk papillary thyroid carcinoma (83).
Recent data indicate that thyroid hormone suppressive
therapy that yields serum TSH levels in the subnormal
range also improves overall survival of patients with
stage II differentiated thyroid cancer, but no addition-
al improvement is associated with further degrees of
thyroid hormone suppression (84). These data rein-
force our Guideline recommendations: more aggres-
sive thyroid hormone suppressive therapy is warranted
in high-risk patients, whereas less aggressive thyroid
hormone suppressive therapy aimed to maintain TSH
levels slightly below normal is indicated in low-risk
patients. Moreover, TSH levels may be considered of
prognostic significance, and add value to thyroglobu-
lin (Tg) measurement, which remains the most impor-
tant predictor of outcome currently available for oper-
ated thyroid cancer patients (85-87).
Images
Nodule appearance on ultrasonography, together with
ultrasound-guided fine-needle aspiration cytology,
and neck exam during thyroid cancer follow-up are
cornerstones of the current management of thyroid
lesions. As more comprehensively discussed elsewhere
in this issue of the ABE&M, ultrasonography is supe-
rior to other imaging methods, such as magnetic reso-
nance imaging or computed tomography scan, except
in particular cases (88,89).
More recently, 18F-FDG PET/CT has emerged
as a promising imaging modality to evaluate thyroid
malignancies, as extensively discussed in another man-
uscript of this issue of the ABE&M. PET and
PET/CT are highly sensitive for Tg and/or radioio-
dine negative-scan thyroids, primary, poorly differenti-
ated or anaplastic tumors, and metastatic lesions (90).
However, their role as predictors of thyroid tumor
aggressiveness remains to be evaluated.
Fractal dimension
Cell structural and biochemical features change with
increasing aggressiveness of a neoplasia. Morphomet-
ric and texture analyses of whole tissue sections or
individual cells are simple, reproducible and inexpen-
sive. Staining can be done on routine slides. Patholo-
gists have proposed the fractal dimension of nuclear
chromatin as a prognostic factor in some tumors, such
as lymphoblastic leukemia (91), myelodysplastic syn-
dromes (92) and laryngeal carcinoma (93). This is a
promising method that may estimate patients’ out-
come early on a cytological fine-needle aspirate, since
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it has also been used for fine-needle aspirates from
breast cytology (94). Recent data suggest that this
technique may be applied to thyroid and possibly be
useful in predicting aggressiveness (95).
CONCLUSION
Screening tools designed to identify individuals at risk for
thyroid nodule cancer are of extreme necessity. Some
clinical and epidemiologic features, among other factors,
have proved to be important in the identification of indi-
viduals at risk. However, an appropriate management
algorithm should balance sensitivity in detecting malig-
nancy against the costs of an additional evaluation, which
poses considerable costs to the patient and to society
(96,97). Likewise, the management of patients diagnosed
with thyroid tumors demands the understanding of the
factors that drive follicular cells towards a non-return path
of dedifferentiation. New promising tools have been
developed and hopefully we will soon be able to sort out
aggressive cases from the vast majority of indolent thyroid
cancers that, perhaps in a not so distant future, will be
merely observed without invasive intervention.
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